Bullish & Foolish
Full SANA fundamentals All 466 on the Survival Watch

SANASana Biotechnology, Inc.

Is Sana Biotechnology struggling financially?

Yes, by its own account. Sana Biotechnology told the SEC on 11 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

  • Restructuring

    For example, we have conducted several portfolio prioritizations to consolidate our resource allocation to fewer programs, resulting in, among other things, workforce reductions.

    Form 10-Q, filed 11 May 2026. Read it on SEC.gov

  • Safety findings

    Integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen, and severe adverse events.

    Form 10-Q, filed 11 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$1.2B
Source filing
10-Q 11 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Oct 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$57.1M

÷

Cash burned over the last 12 months

$144.8M

What Sana Biotechnology told the SEC

…current capital resources may not be sufficient to fund its planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to the Company's ability to continue as a going concern. The Company's ability to continue as a going concern will depend on, among other things, its ability to obtain additional funding and appropriately manage the amount of cash used to…

Sana Biotechnology, Inc., Form 10-Q, filed 11 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 20.3% share-count increase The company issued stock. Each share now owns 16.9% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 63% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt